Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.

Vardeny O, Claggett B, Vaduganathan M, Beldhuis I, Rouleau J, O'Meara E, Anand IS, Shah SJ, Sweitzer NK, Fang JC, Desai AS, Lewis EF, Pitt B, Pfeffer MA, Solomon SD, TOPCAT Investigators. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. JACC. Heart failure. 2019 Dec 1; 7(12):1022-1028.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

OBJECTIVES: The authors examined efficacy and safety of spironolactone by age in the Americas region (N  =  1,767) of the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial. BACKGROUND: Heart failure with preserved ejection fraction disproportionately affects older adults who may exhibit changes in physiology and variable pharmacokinetics. METHODS: TOPCAT enrolled patients with heart failure and a left ventricular ejection fraction  = 45% who were age 50 or older with an estimated glomerular filtration rate  = 30 mL/min/1.73 m and prior heart failure hospitalization or elevated natriuretic peptide levels. Participants were randomized to spironolactone or placebo with a mean follow-up duration of 3.3 years. We assessed treatment effect and safety by protocol-defined age categories ( < 65, 65 to 74, and  = 75 years). RESULTS: The mean age was 72 ± 10 years (range 50 to 97 years) with 41% over the age of 75 years. Participants  = 75 years were more commonly women and white and had a lower body mass index and estimated glomerular filtration rate compared with the younger age categories. Spironolactone reduced the primary composite outcome compared with placebo across all age categories (p interaction  =  0.42). However, spironolactone was associated with an increased risk of the safety endpoint (hazard ratio: 2.54; 95% confidence interval: 1.91 to 3.37; p  <  0.001), particularly in older age groups (p interaction  =  0.02). Findings in the whole TOPCAT cohort were consistent with results from the Americas region. CONCLUSIONS: In this post hoc, exploratory analysis of the TOPCAT trial data from the Americas region, although there was no effect of age on efficacy, there were considerable effects of age on increased rates of adverse safety outcomes. These results should be weighed when considering spironolactone for older heart failure with preserved ejection fraction patients. (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist [TOPCAT]; NCT00094302).